A Claudio Cuello, OC, MD, DSc, FRSC, FMedSci, FMedSci

1985- Pharmacology And Therapeutics McGill University, Montreal, QC, Canada 
Alzheimer's Disease, cognitive behavior, neurochemistry, immunocytochemistry, neuropharmacology and molecular biology.
"A Claudio Cuello"

Since 2003, he has been the Charles E. Frosst/Merck endowed Chair in Pharmacology at McGill University. He leads a research team on multidisciplinary aspects (cognitive behavior, neurochemistry, immunocytochemistry, neuropharmacology and molecular biology) of brain aging and Alzheimer’s disease neuropathology. The Cuello Lab is comprised of talented and motivated colleagues focused on unravelling the earliest biochemical-pathological events of the Alzheimer’s pathology as well as searching for early biomarkers and novel experimental therapies to arrest or revert the early Alzheimer’s pathology. His group has recently made important contributions to the understanding of CNS trophic factor deregulation both in Alzheimer’s disease and in Down syndrome.

He is a current Visiting Professor at Oxford University and the past Toh Chin Chye Visiting Professor in Molecular Biology & Medicine at the National University of Singapore, and past Adjunct Professor in Neuropharmacology at the Scripps Institute (La Jolla) He has made pioneering publications on dendritic release of neurotransmitters, the localization and role of central and peripheral neuropeptides, trophic factor-induced repair and synaptogenesis, novel applications of monoclonal antibodies in the neurosciences and the generation of novel transgenic models of the Alzheimer's-like amyloid pathology. He has co-discovered bi-specific monoclonal antibodies with Cesar Milstein (a Nobel Laureate) and his contributions to the hybridoma technology have been highlighted in a 2013, MRC (UK), on line exhibition: www.whatisbiotechnology.org/exhibitions/milstein/patents and in the Laura Marks’ book “The Lock and Key” of Medicine: Monoclonal antibodies and their transformation of healthcare” , Yale Universiy Press, NY, 2015.

His initial research activities have been conducted at the University of Buenos Aires, in an Antarctic Research Station, at the Buenos Aires Institute of Biology and Experimental Medicine. Later, joined the William Ganong Lab as NIH Post-Doctoral Fellow at UCSF (USA) and later the Leslie Iversen Group at the Cambridge MRC of Neurochemical Pharmacology (England). He has been Assistant Professor at the Buenos Aires University Faculty of Pharmacy and Biochemistry (Argentina). From 1975 to 1978 he was MRC Scientific Staff at the Neurochemical Pharmacology Unit at Cambridge University and from 1978 to 1985 he was Lecturer (Associate Professor) at the Oxford University Department of Pharmacology as well as E.P. Abraham Senior Research Fellow and Medical tutor at Lincoln College.

From 1985 at McGill, he has been serving as Departmental Chair, Research Chair, Senator, founder and Chair of the Brain@McGill (a University-wide Committee fostering International Partnerships in the Neurosciences). His past trainees presently occupy important positions in the industry (Pfizer, Merck, Boehringer), academia (Professors and Head of Department at London University, Imperial College London, Harvard, UCLA, McGill and other ) and the Director of the ALS at the Cleveland Clinic.

He has received numerous recognitions such as the Estela A de Goytia Award of the Argentina Society for the Advancement of Science, the Robert Feulgen Award (Germany), the Iberdrola Visiting Professorship Award (Spain), the Grass Foundation Traveling Scientist Award, the Heinz Lehman Award and the Novartis Award of the Canadian Pharmacological Society. He has been made Honorary Professor of the Norman Bethune University (China) and of the Faculty of Pharmacy and Biochemistry, University of Buenos Aires (Argentina). He has been named Honorary Citizen of New Orleans (USA), invested as Doctor Honoris Causa at the Federal University of Ceara (Brazil), Foreign Member of the Real Academy of Medicine and Surgery, Murcia, Spain and of Honorary Doctor in Medicine of Kuopio University (Finland), Professor Honoris Causa of the Favaloro University, Argentina and recipient of the LSU (New Orleans) Chancellor’s Award and Lecture for contributions to the Neuroscience. He is recipient of the 2015 “Raices” (Roots) Prize of the Argentine Ministry of Science and Technology for his international contributions.

Dr. Cuello has been inducted as Fellow of the Royal Society of Canada. His passage through science has been included in the Society for Neuroscience, (USA) series of "The History of Neuroscience in Autobiographies" (Academic Press, NY, 2000. ed. Larry R. Squire, Academic Press, NY, 2001). In 2011 he was inducted as an "Officer of the Order of Canada" by the Governor General of Canada for his contributions to the Neurosciences and Alzheimer's research and in 2018 inducted as Fellow of the Academy of Medical Sciences in London.

He has authored over 400 scientific publications and has been named Highly Cited Neuroscientist by the ISI (Institute of Scientific Information, USA). His current "H-index" is 92 with over 29,000 citations (Google Scholar). He has given a number of "named" lectures in Europe and North America and he is frequently invited to give lectures at major international meetings.
(Show less)

Mean distance: 13.39 (cluster 11)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Navas Guimaraes ME, Lopez-Blanco R, Correa J, et al. (2021) Liver X Receptor Activation with an Intranasal Polymer Therapeutic Prevents Cognitive Decline without Altering Lipid Levels. Acs Nano
Habif M, Do Carmo S, Báez MV, et al. (2020) Early Long-Term Memory Impairment and Changes in the Expression of Synaptic Plasticity-Associated Genes, in the McGill-R-Thy1-APP Rat Model of Alzheimer's-Like Brain Amyloidosis. Frontiers in Aging Neuroscience. 12: 585873
Pentz R, Iulita MF, Ducatenzeiler A, et al. (2020) Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Flores-Aguilar L, Iulita MF, Kovecses O, et al. (2020) Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain : a Journal of Neurology
Pentz R, Iulita MF, Mikutra-Cencora M, et al. (2020) A new role for matrix metalloproteinase-3 in the NGF metabolic pathway: Proteolysis of mature NGF and sex-specific differences in the continuum of Alzheimer's pathology. Neurobiology of Disease. 105150
Kang MS, Aliaga AA, Shin M, et al. (2020) Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. Molecular Psychiatry
Pentz R, Iulita MF, Ducatenzeiler A, et al. (2020) The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease. Molecular Psychiatry
Hampel H, Vergallo A, Caraci F, et al. (2020) Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology. 108081
Hampel H, Caraci F, Cuello AC, et al. (2020) A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology. 11: 456
Welikovitch LA, Do Carmo S, Maglóczky Z, et al. (2020) Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proceedings of the National Academy of Sciences of the United States of America
See more...